General: Aminoglycoside-induced deafness (AID) is not a curable condition. Instead, treatment focuses on managing hearing loss. AID is bilateral and severe to profound, occurring within a few days to weeks after administration of any amount (even a single dose) of an aminoglycoside antibiotic. About 40% of individuals with a mutation in the MTRN1 gene who have not received aminoglycoside antibiotics develop hearing loss by age 30. By age 65, this proportion increases to 80%.
Hearing aids: People with AID who experience hearing loss may benefit from hearing aids. These battery-operated devices allow people to hear a greater range of sounds by amplifying sounds and are available in three basic styles: behind the ear, in the ear, and inside the ear canal. Patients should talk to their healthcare provider to determine the type of hearing aid that is best for them. A behind-the-ear device is used for mild-to-profound hearing loss. The device is worn behind the ear and is attached to a plastic ear mold inside the outer ear. In-the-ear hearing aids are worn inside the outer ear and are used for mild-to-severe hearing loss. Canal hearing aids are smaller hearing aids that fit inside the patient's ear canal. They are used for mild-to-moderately severe hearing loss.
If hearing loss is severe, patients may benefit from cochlear implants. These electronic devices are surgically implanted inside the ears. Unlike a hearing aid, which amplifies sound, a cochlear implant compensates for damaged parts of the inner ear.
You should read product labels, and discuss all therapies with a qualified healthcare provider. Natural Standard information does not constitute medical advice, diagnosis, or treatment.General: Aminoglycoside-induced deafness (AID) is not a curable condition. Instead, treatment focuses on managing hearing loss. AID is bilateral and severe to profound, occurring within a few days to weeks after administration of any amount (even a... More